A randomized trial to investigate the efficacy and safety of once-daily liraglutide 1.8 mg in Japanese adults with type 2 diabetes exhibiting an inadequate response to liraglutide 0.9 mg.

Seino, Yutaka; Miyoshi, Hideaki; Bosch Traberg, Heidrun; Divyalasya, T V S; Nishijima, Keiji; Terauchi, Yasuo

Seino, Yutaka; Miyoshi, Hideaki; Bosch Traberg, Heidrun; Divyalasya, T V S; Nishijima, Keiji; Terauchi, Yasuo.

Affiliation

Seino Y; Kansai Electric Power Hospital, Osaka, Japan.
Miyoshi H; Kansai Electric Power Medical Research Institute, Osaka, Japan.
Bosch Traberg H; Division of Diabetes and Obesity, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
Divyalasya TVS; Novo Nordisk A/S, Søborg, Denmark.
Nishijima K; Novo Nordisk Service Centre India Private Ltd, Bangalore, India.
Terauchi Y; Novo Nordisk Pharma Ltd, Tokyo, Japan.

J Diabetes Investig ; 13(8): 1321-1329, 2022 Aug.

Article de En | MEDLINE | ID: mdl-35285173

Sujet(s)
Mots clés

Glucagon-like peptide-1; Liraglutide; Type 2 diabetes mellitus

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Diabète de type 2 / Liraglutide / Hypoglycémiants Type d'étude: Clinical_trials Limites: Adult / Humans Pays/Région comme sujet: Asia Langue: En Journal: J Diabetes Investig Année: 2022 Type de document: Article Pays d'affiliation: Japon Pays de publication: Japon

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google